Skip to main content

Table 5 Correlation between VLDLR II expression and clinical features in 51 Lung cancer patients

From: Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers

Parameters Number VLDLR II fold P
Age at diagnosis    
≥ 55 years 30 1.16 ± 0.25 0.781
< 55 years 21 1.11 ± 0.34  
Gender    
Male 35 1.12 ± 0.31 0.424
Female 16 1.19 ± 0.37  
Body weight    
≥ 60 kg 19 1.15 ± 0.22 0.823
< 60 kg 32 1.13 ± 0.32  
TC    
> 5.20 mmol/L 12 1.03 ± 0.20 0.096
≤ 5.20 mmol/L 39 1.16 ± 0.30  
TG    
> 1.70 mmol/L 9 1.01 ± 0.35 0.166
≤ 1.70 mmol/L 42 1.17 ± 0.27  
Histological grade    
Well to moderately differentiated 38 1.11 ± 0.29 0.133
Poorly differentiated 13 1.25 ± 0.27  
Tumor size    
≥ 5 cm 22 1.20 ± 0.30 0.254
< 5 cm 29 1.09 ± 0.28  
Lymph node metastasis    
Negative 15 1.01 ± 0.37 0.090
Positive 36 1.19 ± 0.23  
Distant metastasis    
Negative 40 1.06 ± 0.26 0.008*
Positive 11 1.36 ± 0.29  
TNM stage    
Stage I-II 25 1.06 ± 0.27 0.061
Stage III-IV 26 1.25 ± 0.29  
Histological type    
adenocarcinoma 18 1.22 ± 0.29 0.190
squamous cell carcinoma 24 1.11 ± 0.31  
small cell carcinoma 6 1.03 ± 0.19  
adeno-squamous carcinoma 3 1.09 ± 0.07  
  1. Folds (VLDLR II protein in tumor/in normal) in mean ± SD. VLDLR II measured by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG, triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were performed by Mann-Whitney test (for 2 groups) or Kruskal-Wallis test (for > 2 groups).
  2. *P < 0.05 is considered significant.